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Dear Sir 
Faecal calprotectin is recommended and widely used as a biomarker to 
differentiate between inflammatory bowel disease and irritable bowel 
syndrome.1 Assays require extraction of calprotectin from stool prior to its 
measurement but there is no standardised extraction method. Manual weighing, 
a time-consuming process, is considered the gold standard extraction method. 
Commercially available extraction devices are quicker, simple to operate and 
manufacturers claim comparable performance to manual weighing.  It has, 
however, been recently reported that calprotectin results measured from 
Calex® Cap extracts were higher (mean bias 33%) compared to weighing method 
extracts. 2 We, therefore, re-evaluated the BÜHLMANN Calex® Stool 
Extraction Devices (BÜHLMANN LABORATORIES AG Schönenbuch, 
Switzerland) 3 and compared it to manual weighing extraction method.  
Calprotectin concentrations in extracts following extraction with the Calex® 
and the manual weighing method were compared in 56 homogenised stool 
samples and in 11 external quality assurance (EQA) samples. Inter-batch 
imprecision and stability of extracts were also evaluated. Extracts were 
analysed for calprotectin using BÜHLMANN fCAL® turbo reagent (Alpha 
Laboratories Ltd, Eastleigh, England) on an Abbott ARCHITECT c16000 (Abbott 
Diagnostics, Abbott Park, IL, USA).  
After exclusion of 14 paired results below the limit of quantitation, Passing-
Bablok linear regression of results between 26 µg/g and 1487.9 µg/g showed a 
constant negative bias (intercept) of -5.53 µg/g (95% confidence interval -18.33 
µg/g to 14.42 µg/g) and a proportional bias (slope) of 1.02 µg/g (95% confidence 
interval 0.84 µg/g to 1.14 µg/g) (Figure). Regression analysis contained 0 and 1 
for 95% CI for intercept and slope respectively. A Bland-Altman difference 
plot demonstrated that the Calex® extraction devices had a mean bias of 1% 
(95% confidence interval of -9.1 to 11%) relative to the manual weighing method 
(Figure). Interpretation of the results was concordant for 44 (79%) of the 56 
samples. There was no negative (≤50 µg/g) to positive (≥100 µg/g) discordance 
between the results. Result interpretation was altered as follows: 4/56 negative 
by manual weighing but equivocal (50-100 µ/g) by Calex®, 3/56 equivocal by 
manual weighing but positive by Calex® and 5/56 were positive by manual 
weighing and equivocal by Calex®. Eleven EQA samples extracted using Calex® 
devices compared well to the method laboratory trimmed mean (MLTM) 
produced from results of 12 laboratories over four distributions. Mean bias for 
Calex® versus MLTM across the four distributions was 10.7% (UK NEQAS bias 
limit = 75%). Eight (73%) of the eleven samples were within ± 1 standard 
deviation of the MLTM.  Inter-batch imprecision using the Calex® extraction 
devices was similar to the weighing extraction method (29.9% Calex® vs. 26.5% 
manual weighing at mean concentration of 29 µg/g and 9.3% Calex® vs. 12.3% 
manual weighing at mean concentration of 123 µg/g). Imprecision at low 
concentrations was difficult to quantify as several values were below the limit 
of quantitation of the assay but all values produced a negative result for both 
extraction methods. Faecal calprotectin in extracts prepared by Calex® devices 
was not significantly affected by storage at 4 ˚C over 5 days. The percentage 
difference at day 5 compared to day 0 for samples 1, 2 and 3 was 11%, 32% and 
22%, respectively. The difference between baseline and repeat at day 5 did not 
exceed the difference expected due to imprecision of the assay. 
Considering the non-homogenous nature of stool samples, Calex® devices 
demonstrate similar accuracy and imprecision to the gold standard manual 
method for extracting faecal calprotectin. Our results differ from those 
previously reported; 2 all assays in this report were performed by a single 
operative and this may help to explain the discrepancy.  Compared to the manual 
method, the Calex® was easy to use, reduced staff time, used fewer 
consumables (such as inoculation loops and centrifugation tubes), and improved 
health and safety by avoiding further direct contact with the specimen after 
initial sampling. 
 
Calex® devices are fit for purpose, easy to use and offer a quicker extraction 
process compared with manual weighing and will therefore enable increasing 
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Figure: Comparison of manual weighing to commercial Calex® devices for the 
measurement of calprotectin following extraction from stool samples. A) 
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